Clinic Observation on Diffuse Large B-cell Lymphoma Treated by Rituximab

ObjectiveTo observe the curative effect and drug adverse reaction of rituximab in treatment for diffuse large B-cell lymphoma (DLBCL). Methods R-CHOP-21 regimen was employed to 40 patients with DLBCL. ResultsThe curative effects of the short-term were 15(37.5%) cases of complete response(CR),14(35%) cases of partial response(PR) and response rate(RR) was 72.5%. In drug adverse reactions, skin rash or cardiac rhythm of degree Ⅳ was 1 case respectively. ConclusionThe rituximab showed strongly short-term effect with moderate adverse reaction degree Ⅳ of skin toxicity and cardiac rhythm had to be found early and treated immediately.